Type-1 Interferon To Prevent Leukemia Relapse After Allogeneic Transplantation

John Magenau, MD and colleagues report in Blood Advances that augmenting early graft-vs-leukemia response by prophylactic Type 1 IFN may potentially reduce rates of leukemic relapse after HCT in very high risk AML.